Comparative bioavailability and steady state fluctuations of tegretol commercial and carbamazepine oros tablets in adult and pediatric epileptic patients

Biopharmaceutics & Drug Disposition

Volumn 13, Issue 8, 1992, Pages 559-569

  Thakker, Kamlesh M ^a   Mangat, Surinder ^a   Garnett, William R ^b   Levy, René H ^c   Kochak, Gregory M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Carbamazepine; OROS; Relative bioavailability; Tegretol

Indexed keywords

CARBAMAZEPINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; SCHOOL CHILD; STEADY STATE; SUSTAINED RELEASE PREPARATION; TABLET;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHILD; COMPARATIVE STUDY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMAN; MALE; MIDDLE AGE;

EID: 0026781584     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.2510130802     Document Type: Article

References (10)

1. Report on the antiepileptic action of Tegretol
2. Trigeminal neuralgia: Its treatment with a new anticonvulsant drug (G‐32882)
3. Carbamazepine pharmacology and clinical use
4. Drugs effective in the therapy of the epilepsies: Carbamazepine
5. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10, 11‐epoxide: An update
6. Double‐blind cocaine reduction in unmotivated crack users: Efficacy of carbamazepine versus placebo in a short term crossover design
7. Other antiepileptic drugs
8. Clinical pharmacokinetics of carbamazepine
9. Simultaneous liquid‐chromatographic determination of carbamazepine and its epozide metabolite in plasma
10. Analysis of a two‐period crossover design in a multicenter clinical trial